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Lectinss (CBAs), such as the mannose-speciﬁc Hippeastrum hybrid agglutinin (HHA) and
the GlcNAc-speciﬁc Urtica dioica agglutinin (UDA), frequently select for glycan deletions in all different
domains of HIV-1 gp120, except in the V1/V2 domain. To reveal the underlying mechanisms, a broad variety
of 31 different virus strains containing one or several N-glycan deletions in V1/V2 of the gp120 of the X4-
tropic HIV-1NL4.3 were constructed by chimeric virus technology. No co-receptor switch to CCR5 was
observed for any of the replication-competent mutant virus strains. With a few exceptions, the more glycans
were deleted in the gp120 V1/V2 domain, the more the replication capacity of the mutant viruses became
compromised. None of the mutant virus strains showed a markedly decreased sensitivity to the inhibitory
activity of HHA and UDA. Instead, an up to 2- to 10-fold higher sensitivity to the inhibitory activity of these
CBAs was observed. Our data may provide an explanation why glycan deletions in the gp120 V1/V2 domain
rarely occur under CBA pressure and conﬁrm the important functional role of the glycans in the HIV-1 gp120
V1/V2 domain. The gp120 V1/V2 loop glycans of HIV-1 should therefore be considered as a hot spot and
novel target for speciﬁc therapeutic drug intervention.
© 2008 Elsevier Inc. All rights reserved.Introduction
The gp120 envelope glycoprotein of HIV-1 is a heavily glycosylated
protein and contains ∼20 to 30 consensus recognition sites for N-
linked glycosylation (i.e. N-X-S/T where X=any amino acid except P).
The carbohydrate content of gp120 comprises approximately half of
the molecular weight of the entire molecule (Geyer et al., 1988).
Studies of recombinant gp120 expression in CHO cells show that all
the 24 potential N-glycosylation sites in HIV-1IIIB gp120 are indeed
occupied by N-linked glycans (Leonard et al., 1990). Approximately 11
out of 24 of these glycans were determined to have a high-mannose-
type structure. The N-glycans play an important role in correct folding,
intracellular transport, (co)receptor binding and masking immuno-
dominant domains (i.e. the V3 loop) (Li et al., 1993; Wyatt et al., 1998).
Together with the V1/V2 variable domain, the V3 loop forms a pocket
surrounding the four-stranded antiparallel β-sheet (i.e. the bridgingUDA, Urtica dioica agglutinin;
GlcNAc, N-acetylglucosamine;
Dulbecco minimal essential
lzarini).
.
l rights reserved.sheet), which plays an important role in the co-receptor interaction of
gp120. The overall conformation of the V3 loop together with internal
interactions within the V1/V2 loop is thought to be the primary
determinant for the efﬁcient binding of gp120 to CCR5, CXCR4 or both,
thus deﬁning the cellular tropism of the virus isolate (Hwang et al.,
1991; O'Brien et al., 1990; Ogert et al., 2001; Ross and Cullen, 1998;
Shioda et al., 1992). The V2 domain is part of a disulﬁde-bonded arm of
gp120 that also includes the V1 region. Deletion of the V1/V2 loop has
been shown to result in non-infectious virions (Wyatt et al., 1993)
although other studies have shown that some HIV-1 and SIV strains in
which the V1/V2 domain of gp120 had been deleted were still
replication-competent (Cao et al., 1997). Point mutations in V2 have
also been shown to affect syncytium formation (Sullivan et al., 1993).
The lack of the entire V1/V2 loop (Ogert et al., 2001), the removal of 3
to 5 high-mannose residues from 289 to 448 in the C2–C4 region of
gp120 (Hu et al., 2007) or even the removal of only the single N195
linked glycan (Li et al., 2008) resulted in an increased sensitivity
towards V3 loop-directed antibodies. In addition, deletion of glyco-
sylation sites in the V1 domain of simian immunodeﬁciency virus
(SIV) gp120 resulted in a redirection of B-cell responses to V3 (Cole et
al., 2004). Thus the V1/V2 loop in gp120might partially overlap and/or
affect the antigenic epitopes of the principal neutralizing V3 domain.
Lectins are a class of proteins that interact with carbohydrates. The
majority of these lectins primarily recognize mannose, glucose,
11J. Auwerx et al. / Virology 382 (2008) 10–19galactose, N-acetylglucosamine (GlcNAc), N-acetylgalactosamine
(GalNAc), fucose and/or N-acetylneuraminic (sialic) acid. In addi-
tion, they preferentially interact with a variety of oligosaccharide
glycans composed of one or more of these monosaccharides. It has
been shown that especially the mannose-speciﬁc plant lectins (e.g.
Hippeastrum hybrid agglutinin (HHA)), but also GlcNAc-recognizing
lectins (e.g. Urtica dioica agglutinin (UDA)), show marked potency
to inhibit enveloped viruses such as HIV (for a review see Balzarini,
2006a; Botos and Wlodawer, 2005) and hepatitis C virus (HCV)
(Bertaux et al., 2007). The inhibition of viral entry by carbohydrate-
binding lectins is probably accomplished by crosslinking the
membrane glycoproteins of the virus, resulting in blocking the
entry (or fusion) of the virus into its target cell (Leikina et al.,
2005). We reported previously that mannose-speciﬁc lectins [i.e.
α(1,3)- and/or α(1,6)-mannose-speciﬁc HHA and Galanthus nivalis
agglutinin (GNA); the α(1,2)-mannose-speciﬁc Cyanovirin-N (CV-N),
the non-peptidic small-size α(1,2)-mannose-speciﬁc antibiotic
pradimicin A (PRM-A)] and also the GlcNAc-speciﬁc UDA select
for a unique drug resistance proﬁle that mainly affects the N-
glycosylation pattern of the HIV-1 gp120 (Balzarini et al., 2004;
2005a; 2005b; 2006b; 2007). The resistance mutations predomi-
nantly appeared at asparagine or serine/threonine residues that areTable 1
a. Co-receptor use of glycan-deﬁcient HIV-1 strains and susceptibility to the inhibitory effe
Number Mutations in gp120 V1/V2 domain
NL4.3 – – – – – –
1 N136Q – – – – –
2 – N141Q – – – –
3 – – N156Q – – –
4 – – – N160Q – –
5 – – – N160D – –
6 – – – – N186Q –
7 – – – – – N19
8 N136Q N141Q – – – –
9 N136Q – – N160Q – –
10 N136Q – – – – N19
11 – N141Q – N160Q – –
12 – N141Q – – N186Q –
13 – – N156Q – N186Q –
14 – – N156Q – – N19
15 – – – N160D N186Q –
16 N136Q N141Q N156Q – – –
17 N136Q N141Q – N160Q – –
18 N136Q N141Q – – N186Q –
19 N136Q – – – N186Q N19
20 N136Q – N156Q – N186Q –
21 N136Q – N156Q – – N19
22 – – N156Q – N186Q N19
23 – N141Q – N160Q – N19
24 N136Q N141Q N156Q N160Q – –
25 N136Q N141Q N156Q – N186Q –
26 N136Q N141Q – N160Q – N19
27 N136Q – N156Q N160Q N186Q –
28 N136Q – N156Q – N186Q N19
29 N136Q N141Q N156Q N160Q – N19
30 N136Q – N156Q N160Q N186Q N19
31 N136Q N141Q N156Q N160Q N186Q N19
b. Susceptibility of selected glycan-deﬁcient HIV-1 strains to the inhibitory effect of AMD3
Number Mutations in gp120 V1/V2 domain
NL4.3 – – – – –
3 – – N156Q – –
9 N136Q – – N160Q –
18 N136Q N141Q – – N186Q
26 N136Q N141Q – N160Q –
Data are means of at least 3 independent experiments.
a 50% effective concentration.
b Non-sufﬁcient viable glycan-deﬁcient virus.part of the N-X-S/T N-glycosylation motif on gp120. Intriguingly, in
sharp contrast with the frequently observed glycan deletions at
domains of gp120 other than V1/V2, glycan deletions in the V1/V2
domain of HIV-1 gp120 rarely occur under CBA pressure. The gp120
V1 and V2 region of the T-cell laboratory-adapted HIV-1 strain
NL4.3 contains six recognition sites for N-linked glycosylations (i.e.
N136, N141, N156, N160, N186, N195) which represents approxi-
mately 25% of the total amount of glycans present on gp120.
Among more than 50 virus isolates independently selected under
CBA pressure (harbouring an average number of ∼4–5 glycan
deletions in gp120), only two virus strains contained a glycan
deletion in gp120 V1/V2: one virus strain contained a N160D
mutation in gp120 V2 (Balzarini et al., 2005a), and one virus strain
had a glycan deletion at amino acid position N186 of gp120 V2 due
to mutation of T188 to N188 (Balzarini et al., 2005b). However, the
latter mutation created a new glycosylation site (at amino acid
position 188; 188NXS190). Moreover, the mutations did not occur
as single mutations, but were invariably present in a background of
additional glycan deletions in the other domains of gp120.
To elucidate the underlying mechanism of the virtual lack of
glycan deletions in gp120 V1/V2, we constructed 31 recombinant
mutant virus strains derived from the HIV-1NL4.3 strain withct by CBAs
Co-receptor use Susceptibility to CBA as EC50a
CCR5 CXCR4 HHA (nM) UDA (nM) PRM-A (μM)
– + 7±1 47±11 2.2±0.4
– + 1.0±0.4 13±6 1.7±0.2
– + 1.2±0.4 13±7 2.1±0.1
– + 6±1 60±23 –
– + – – –
– + 4±2 21±13 2.1±0.2
– + 22±1 115±69 2.1±0.06
5Q – + 1.8±0.2 13±2 2.2±0.01
– + 1.0±0.2 13±1 1.6±0.5
– + 4±3 80±34 2.1±0.2
5Q – + 0.8±0.2 5.7±1 2.1±0.1
– + 3±2 47±10 –
– + 1±0.1 14±2 2.0±0.2
– + 1.6±0.8 12±1 2.7±0.0
5Q – + – – –
– + 1.0±0.6 6±2 2.3±0.1
– + 1.6±0.8 14±1 2.2±0.01
– + 5±2 28±15 2.1±0.07
N.V.b N.V. N.V. N.V. N.V.
5Q – + 1.0±0.2 4.6±0.0 3.7±0.5
– + 3±1 21±13 2.2±0.01
5Q – + 2±1 9±4 2.1±0.1
5Q – + – – –
5Q – + 1.0±0.2 5.6±0.0 1.9±0.2
– + 1.7±0.2 16±10 2.2±0.01
– + 1.6±0.8 5±2 2.1±0.03
5Q – + 1.8±0.6 15±6 2.2±0.4
– + 1.4±0.4 11±7 –
5Q N.V. N.V. N.V. N.V. N.V.
5Q – + – – –
5Q N.V. N.V. N.V. N.V. N.V.
5Q N.V. N.V. N.V. N.V. N.V.
100 and sCD4
EC50a (μg/ml)
AMD3100 sCD4
– 0.006±0.004 0.05±0.03
– 0.007±0.002 0.04±0.02
– 0.006±0.003 0.09±0.06
– 0.004±0.002 0.10±0.04
N195Q 0.002±0.001 0.03±0.01
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sites in gp120 V1/V2. All 31 recombinant mutant viruses were
evaluated in cell-based infection assays for infectivity, replication
ﬁtness, co-receptor usage (CXCR4 or CCR5) and sensitivity to HHA
and UDA. HHA and UDA were chosen for their different
carbohydrate speciﬁcity (α(1,3)/α(1,6)-mannose versus GlcNAc).
The viruses were also evaluated against the non-peptidic α(1,2)-
mannose-speciﬁc antibiotic PRM-A.
The observed attenuation of infectivity of the mutant virus strains
and their increased sensitivity to the inhibitory effect of HHA and UDA
may provide a rational explanation of the virtual lack of appearance of
glycan deletions in the gp120 V1/V2 domain under CBA pressure. Our
ﬁndings revealed that the glycan conﬁguration of the gp120 V1/V2
area of HIV-1 may be considered as a hot spot and selective target for
future novel drug development.
Results
Co-receptor usage of the mutant virus strains
A variety of 31 different recombinant virus strains all derived
from the X4-tropic HIV-1NL4.3 strain have been constructed,
containing mutations in either of the six glycosylation motifs in
the HIV-1 gp120 V1/V2 domain, and combinations thereof. Multi-
site directed mutagenesis of the V1/V2 domain of HIV-1 gp120
resulted in a variety of 7 virus strains with 1 mutation, 8 virus
strains with 2 mutations, 8 virus strains with 3 mutations, 5 virus
strains with 4 mutations, 2 virus strains with 5 mutations and 1
virus strain containing 6 mutations (Table 1). The viral tropism of
these recombinant mutant (deglycosylated) virus strains was
evaluated by examining the ability of the mutant viruses to
productively infect U87/CD4+/CCR5+, U87/CD4+/CXCR4+ or U87/
CD4+/CXCR4+/CCR5+ cells. All recombinant viruses for which repli-Fig.1. Viral replication of V1/V2 loopmutant virus strains based on a p24 normalization. The g
deleted N-glycosylation site(s) in the V1 and/or V2 loop was monitored by inoculation of C81
were ﬁxed daily in 2% PFA and monitored on a FACS CantoII ﬂow cytometer for EGFP expre
independent experiments.cation could have been measured invariably infected solely U87/
CD4+/CXCR4+ and U87/CD4+/CXCR4+/CCR5+ cells but not U87/CD4+/
CCR5+ cells (Table 1) and thus kept their exclusive CXCR4-tropism.
Thus, since none of the recombinant virus strains were able to
infect the U87/CD4+/CCR5+ cell cultures, we concluded that glycan
mutations that were exclusively located in the gp120 V1/V2
domain did not result in a co-receptor switch of the laboratory
strain NL4.3 from CXCR4 to CCR5.
Replication ﬁtness of the mutant virus strains upon normalization of
p24 levels
The mutant virus strains lacking the single gp120 V1 domain-
associated N-glycosylation sites N136, N141 or N156 showed quite
similar replication rates compared to HIV-1NL4.3 wild-type (Fig. 1A).
However, the mutant viruses with single gp120 V2-associated
glycan deletions showed a lower replication rate than wild-type
virus (i.e. N186Q and N195Q). The N160Q mutant virus was even
devoid of meaningful replicating capacity. The N160D mutant virus
showed again a recovered replicative potential, although not
comparable with wild-type virus (Fig. 1A). Several double mutated
virus strains behaved virtually identical as wild-type HIV-1
(Fig. 1B). Remarkable are the very compromised replication rates
of the viruses containing V1 N156Q or N136Q in combination with
the N195Q mutation that is located in the carboxy-terminal stem of
the V2 loop. The decreased replication potential of these double
mutated viruses is much more pronounced than expected from the
single mutants (Fig. 1B). Thus, the sugar moiety on position N195
could have a supportive role in entry/fusion and is indispensable
for proper envelope function and replication competence. This is
also conﬁrmed from the data shown in Fig. 1C where the triple
mutants containing the N195Q mutation have very low and highly
compromised replication rates. In contrast, single (Fig. 1A), doublerowth of different virus mutants with single (A), double (B), triple (C) and quadruple (D)
66 cells with equal amounts of HIV-1 p24 antigen. Starting at 1-day post-infection, cells
ssion as a measurement of (mutant) HIV-1 replication. Data are the means of at least 3
Table 2
k- and R2-values for the replication graphs of the mutant glycan-deﬁcient HIV-1 strains
depicted in Fig. 2
Number Mutations in gp120 V1/V2 domain k-value R2
NL4.3 – – – – – – 2.961 0.9999
1 N136Q – – – – – 2.933 1.000
2 – N141Q – – – – 2.484 1.000
3 – – N156Q – – – 2.806 0.9997
4 – – – N160Q – – 0.196 0.9999
5 – – – N160D – – 3.085 0.9999
6 – – – – N186Q – 2.853 0.9995
7 – – – – – N195Q 2.158 0.9988
8 N136Q N141Q – – – – 2.379 0.9999
9 N136Q – – N160Q – – 2.991 0.9999
10 N136Q – – – – N195Q 1.998 0.9995
11 – N141Q – N160Q – – 2.940 0.9999
12 – N141Q – – N186Q – 2.068 0.9972
13 – – N156Q – N186Q – 1.643 0.9999
14 – – N156Q – – N195Q – –
15 – – – N160D N186Q – 2.650 0.9998
16 N136Q N141Q N156Q – – – 1.791 0.9988
17 N136Q N141Q – N160Q – – 2.780 1.000
18 N136Q N141Q – – N186Q – – –
19 N136Q – – – N186Q N195Q 1.927 0.9967
20 N136Q – N156Q – N186Q – 2.646 0.9987
21 N136Q – N156Q – – N195Q 2.081 0.9977
22 – – N156Q – N186Q N195Q – –
23 – N141Q – N160Q – N195Q 1.997 0.9999
24 N136Q N141Q N156Q N160Q – – 1.458 0.9973
25 N136Q N141Q N156Q – N186Q – 1.567 0.9986
26 N136Q N141Q – N160Q – N195Q 2.034 0.9969
27 N136Q – N156Q N160Q N186Q – 1.234 0.9985
28 N136Q – N156Q – N186Q N195Q – –
29 N136Q N141Q N156Q N160Q – N195Q 1.630 0.9995
30 N136Q – N156Q N160Q N186Q N195Q – –
31 N136Q N141Q N156Q N160Q N186Q N195Q – –
13J. Auwerx et al. / Virology 382 (2008) 10–19(Fig. 1B) and triple (Fig. 1C) glycan mutants in the V1 loop do not
have a signiﬁcant effect on the loss of the viral replication capacity.
Quadruple mutant virus strains displayed highly impaired replica-
tion rates. Most of the mutant constructs did not even result in
replication-competent virus (Fig. 1D). This is also the case for the
recombinant viruses with ﬁve mutations of their glycosylation sites
and with a completely deglycosylated gp120 V1/V2 domain-
containing virus strain (Table 1). Interestingly, the budding of
these heavily deglycosylated viruses from the transfected cells was
still possible as observed by a p24 ELISA on the transfection
supernatants (data not shown).
Replication ﬁtness of the mutant virus strains upon normalization of
infectious viral particles
The results of the replication capacity assay normalized by the
amount of infectious particles were plotted on a log scale on the Y-axis
versus the time points post-day 3 as depicted in Fig. 2. The amount of
infected cells was normalized to the percentage infection on day 3
(which was determined to be approximately 0.1%). The resulted k-
values of the exponential functions can be used as a tool to compare
the replication capacity between mutant virus strains and wild-type
NL4.3 and are depicted in Table 2.
The N160Q mutant virus strain was devoid of meaningful
replication capacity. However the N160D mutant virus showed a
replication rate that was close to wild-type virus (Fig. 2A). The
mutant virus strains lacking the single gp120 V2 domain-associated
N-glycosylation site N195 showed a lower replication rate than
wild-type virus. Most double mutant virus strains were endowed
with replication capacities that were inferior to wild-type virus.
When the N136Q mutation was introduced in the (replication-
deﬁcient) N160Q mutant virus the replication capacity was restored
to the level of wild-type virus. Double mutant virus strains
containing the V2-domain-associated N186 or N195 glycan deletion
all showed decreased replication rates compared to wild-type virusFig. 2. Comparison of the replication capacity of mutant V1/V2-loop virus strains based on i
(A), double (B), triple (C) and quadruple (D) deleted N-glycosylation site(s) were recorded in
0.1% infection on day 3 post-inoculation. Cells were ﬁxed daily after day 3 in 2% PFA and m
replication. The data were normalized to the day 3 value and plotted on a log scale versus the
of at least 3 independent experiments.(Fig. 2B). Triple mutants containing the N195 deletion showed also
a decreased replication rate compared to wild-type. The introduced
N195Q mutation resulted in the most impaired virus strains as alsonfectious particle normalization. Growth kinetics of different virus mutants with single
C8166 cells that were infected with an equal amount of infectious particles that result in
onitored on a FACS CantoII for EGFP expression as a measurement of (mutant) HIV-1
time points post-day 3. The k- and R2-values are depicted in Table 2. Data are the means
Table 3
Binding of glycan-deﬁcient virus strains to human CD4
Number Mutations in gp120 V1/V2 domain CD4 binding
(% of wild-type)a
1 N136Q – – – – – 127±9
2 – N141Q – – – – 211±49
3 – – N156Q – – – 127±21
4 – – – N160Q – – 188±42
5 – – – N160D – – 140±21
6 – – – – N186Q – 94±1
8 N136Q N141Q – – – – 237±39
9 N136Q – – N160Q – – 158±27
10 N136Q – – – – N195Q 159±26
11 – N141Q – N160Q – – 180±29
12 – N141Q – – N186Q – 117±20
13 – – N156Q – N186Q 150±25
17 N136Q N141Q – N160Q – – 121±20
23 – N141Q – N160Q – N195Q 71±7
24 N136Q N141Q N156Q N160Q – – 113±26
26 N136Q N141Q – N160Q – N195Q 82±7
a Data are the means of at least 3 independent experiments.
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used as the normalized standard. In general all triple mutant virus
strains showed a decreased replication rate compared to wild-type
(Fig. 2C). This observation is even more pronounced when we
introduced 4 or more deletions in the glycosylation sites of the V1/
V2 loop, all resulting in virus strains with seriously impaired
replication capacity compared to wild-type virus (Fig. 2D).
Susceptibility of deglycosylated HIV-1 strains to the
carbohydrate-binding agents (CBAs), AMD3100 and sCD4
The inhibitory effects of the α(1,3)/α(1,6)-mannose-speciﬁc HHA,
the GlcNAc-speciﬁc UDA, the α(1,2)-mannose-speciﬁc non-peptidic
antibiotic PRM-A, AMD3100 and sCD4 on the expression of EGFP by
the different mutant recombinant viruses in human lymphocyte
C8166 cell cultures are displayed in Table 1. Wild-type HIV-1NL4.3 is
inhibited by HHA at 7±1 nM, by UDA at 47±11 nM and by PRM-A at
2.2±0.4 μM. Higher susceptibility to HHA and UDA was invariably
observed with only a very few exceptions (i.e. the virus strains
containing the single N156 and N186 glycan deletions). The higher
susceptibility of the mutant viruses to these CBAs ranged from 2-fold
to up to 10-fold. There was a close correlation between the degree of
sensitization of the mutant virus strains against the mannose-speciﬁc
HHA and against the GlcNAc-speciﬁc UDA (r=0.853) (Fig. 3). This
observation points to a similar mechanism of sensitization of the
mutant virus strains against both types of CBAs. In fact, both HHA and
UDA bind carbohydrate conﬁgurations that are present in the interior
structure of the complex-type glycans present in gp120 V1/V2. In
contrast to HHA and UDA, PRM-A acts at the surface of the high-
mannose-type glycans, and did not show an increased antiviral
activity (Table 1). Its antiviral activity ranged between 1.6 and 3.7 μM
irrespective the nature of the glycan site mutations in V1/V2 gp120
(EC50 wild-type virus: 2.2±0.4 μM).
In addition, the antiviral activity of the CXCR4 antagonist AMD3100
on selected mutant deglycosylated recombinant viruses (EC50 ranging
from 0.02 to 0.07 μg/ml) did not show signiﬁcant differences
compared to wild-type HIV-1NL4.3 (EC50 of 0.06 μg/ml). Also, sCD4
showed very similar antiviral activity against the selected mutant
deglycosylated strains (EC50 ranging from 0.03 to 0.1 μg/ml) compared
to wild-type HIV-1NL4.3 (EC50 of 0.05 μg/ml) (Table 1).
Binding of mutant deglycosylated HIV-1 strains to human sCD4
We determined the binding capacity of a ﬁxed amount of wild-
type and mutant deglycosylated viruses to human sCD4 that was
immobilized on a 96-well maxisorp surface (Table 3). The observed
OD-values related to the binding of the mutant deglycosylated viruses
to sCD4were similar or higher than those observed for wild-type HIV-Fig. 3. Correlation between the sensitization of the mutant HIV-1 strains against the
mannose-speciﬁc HHA and against the GlcNAc-speciﬁc UDA. Different symbols were
used for single (◆), double (▲), triple (■) and quadruple (X) virus mutants.1NL4.3, except for the viruses bearing the N141Q/N160Q/N195Q or
N136Q/N141Q/N160Q/N195Q mutations that had a CD4-binding
capacity of 71±7% and 82±7% of wild-type, respectively.
Discussion
The role of HIV-1 (and SIV) gp120 envelope N-glycans in
neutralizing antibody response has been investigated by mutagenesis
technology (Quinones-Kochs et al., 2002; Reitter and Desrosiers,1998;
Wolk and Schreiber, 2006). These studies revealed that mutant virus
strains lacking glycans on position N136 and N141 in V1 and glycans
on position N160 and N186 in V2 showed a high sensitivity against
human serum antibodies from HIV-1-infected individuals. Viruses
with gp120 V1/V2 loop deletions show an impaired ability to form
syncytia, however, a deletion of the entire V1/V2 loop of HIV-1 can still
result in an infectious virus but with impaired entry capacity in
comparison to wild-type virus (Cao et al., 1997), which could indicate
that an intact V1/V2 loop is indispensable for optimal viral infectivity
and replication.
Mutations in V3 which are sufﬁcient for changing co-receptor use
from CCR5 to CXCR4 often entail a high risk for the virus, leading to
major loss of entry ﬁtness or even resulting in lethality (Huang et al.,
2005; Hwang et al., 1991). Mutations in or near the gp120 V1/V2 loop
were able to compensate for the deleterious V3 mutations and may
even be needed to precede some V3 mutations to permit efﬁcient
virus survival (Pastore et al., 2006). In contrast, deletion of the
surrounding glycans of the V3 loop can result in a mutant virus with
an increased infectivity (Polzer et al., 2001) and the deletion of the
sole complex-type glycan within the V3 loop itself inﬂuences viral
tropism (Polzer et al., 2002).
In the current study no viral tropism change was observed for any
of the replication-competent viruses with single glycan deletions or
for any of the multiple combinations of glycan deletions that were
introduced in the gp120 V1/V2 loop in the presence of a wild-type
gp120 V3 loop genetic background. It can, of course, not be excluded
that one or several glycan deletions in gp120 V1/V2 may allow co-
receptor switch in the presence of well-deﬁned mutations in the V3
loop, given the communication and interaction between the V3 and
V1/V2 domains of gp120 and the co-receptor interaction with the
bridging sheet of gp120.
The replication competence of the mutant virus strains have been
compared with wild-type virus starting from equal amounts of p24
(Fig. 1, Table 1) and from equal amounts of infectivity units (Fig. 2,
Table 2). The results and conclusions from both sets of experiments
were in agreement with each other. Analysis of the replication
competence of the mutant virus strains revealed striking differences
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Whereas V1 loop glycan mutations had little, if any effect on viral
infectivity, glycan mutations in the V2 loop (i.e. N186Q and N195Q)
had a dramatic impact on the infection capacity of the mutant
virus strains. This phenomenon is in agreement with previous
ﬁndings made by other investigators (Ly and Stamatatos, 2000;
Stamatatos et al., 1998; Wu et al., 1995). Moreover, none of the V1
glycan deletions were able to compensate for the infectivity loss of
V2 glycan deletions when combined, and multiple paired glycan
deletions in V1 synergistically compromised virus infectivity. These
observations point to a serious restriction of the glycan conﬁgura-
tion in gp120 V1/V2, and a potential limitation of ﬂexibility of this
part of the viral envelope in response to gp120-targetting (i.e. CBA)
drugs. Most likely, abrogation of glycosylation in the V1/V2 area of
HIV-1 gp120 would affect the tertiary structure of the protein
(through a direct effect on correct protein folding), resulting in an
altered infection capacity (i.e. lower ﬁtness). Indeed, evidence has
been presented for a role of speciﬁc V2 glycans in the correct
folding of the V1/V2 domain (Wu et al., 1995), and lack of proper
folding of V1/V2 may eventually result in a less optimal overall
envelope conformation directly affecting infectivity efﬁciency. The
different infectivity capacity of the N160Q and N160D mutant virus
strains suggests that not only the location of the mutated amino
acid site, but also the nature of the mutated amino acid is
important to eventually determine its effect on mutant virus
infectivity and that the degree of glycosylation of gp120 does not
solely account for viral infectivity. Also, the marked ﬂuctuating
differences of infectivity potential of the N160Q, N141Q/N160Q,
N136Q/N141Q/N160Q and N136Q/N141Q/N156Q/N160Q mutant
virus strains cannot be explained if the infectivity potential of the
viruses is solely ascribed to the presence or absence of the glycans.
Crystal structure studies on the entire gp120 would be needed to
distinguish between the effect of amino acid changes on the one
hand, or solely glycan deletions on the other hand on the gp120
conformation and related infectivity potential of the mutant
viruses.
In an adapted HIV-1ADA strain the deletion of the entire gp120
V1/V2 loop allowed a CD4-independent entry of the virus and
gp120 binding to CCR5 (Kolchinsky et al., 2001). In this context it
was also shown that the elimination of only one single glycosyla-
tion site at position N195 in the V1/V2 stem was sufﬁcient for this
CD4-independent gp120 binding to CCR5 and for HIV-1 entry into
CD4-negative cells expressing CCR5 (Kolchinsky et al., 2001). This
was not observed with the single N195 mutant HIV-1NL4.3 in our
study. However, we found that the deletion of the N-glycosylation
site at the gp120 position N195 of the NL4.3 virus strain (the N195
glycan in HIV-1NL4.3 corresponds to the N197 glycan in HIV-1IIIB or
HIV-1ADA) resulted in a lower replication rate, in particular when
the mutation was combined with other glycan deletions in the
gp120 V1/V2 domain, such as N136 or N156. Thus, the disappear-
ance of the glycan at N195 seems to compromise the interaction of
HIV-1NL4.3 with its CD4 or CXCR4 co-receptor, resulting in reduced
viral infectivity.
It is currently unknown whether the glycan mutations have an
effect on the level of mutant env production and/or incorporation of
env in the virions. Lower env levels in the virion may affect CBA
sensitivity and infection potential of such mutant viruses. Therefore,
determination of the number of env molecules in the mutant virus
particles would be interesting to address this issue and to obtain
better insights in the structural and functional events that are caused
by the glycan deletions in the envelope of HIV-1. From the observation
that the inhibitory effect of sCD4 and the CXCR4 antagonist AMD3100
on HIV replication is very similar against wild-type and mutant
deglycosylated HIV-1NL4.3 we can conclude that glycan deletions in the
V1/V2 domain have no marked effect on CD4 receptor or CXCR4 co-
receptor binding. This observation was conﬁrmed in a CD4-bindingassay where the mutant deglycosylated viral strains had a rather
minor effect on their CD4-binding capacities compared to wild-type
HIV-1NL4.3.
Exposure of HIV-1 to escalating CBA concentrations invariably
results in the appearance of glycan deletions in gp120 (Balzarini,
2007a; 2007b and references therein). There is a preference for
deletions of high-mannose type glycans, and of glycans that are
located in areas on gp120 different from V1/V2. Indeed, a glycan
deletion in the V1/V2 domain (N160 or N186) was very seldom
observed (only 2 times) to have occurred among a total number of
more than 50 independently selected mutant virus strains. In all other
virus strains, the 6 complex-type glycans in gp120 V1/V2 were kept
intact. Such conservation of the glycans in the HIV-1 gp120 V1/V2
domain under CBA drug pressure is unusual given the fact that
approximately 25% of all glycans on gp120 resides in this envelope
domain. This observation can now be explained by our ﬁndings that
virtually all mutant virus strains obtained in our study showed an
increased sensitivity (2- to up to 10-fold) to the mannose-speciﬁc
(HHA) and GlcNAc-speciﬁc (UDA) CBAs. In addition, given our ﬁndings
that glycan deletions in the gp120 V1 and particularly in the gp120 V2
loop seriously compromise the viruses' infectivity potential, it seems
obvious that such mutant virus strains are highly unlikely to emerge
under the continuous pressure of the HHA and UDA CBAs. The only
exceptions are the N160 and N186 HIV-1 gp120 mutants that have
been (only once) observed to occur in cell culture under CBA pressure.
It may not be co-incidence that the N186 gp120 HIV-1 mutant is
indeed less sensitive to HHA and UDA suppression than wild-type
virus, and thus could be expected to be selected in the presence of
HHA or UDA, given its fairly good replication competence. The N156
HIV-1 gp120 mutant has also a good replication competence but its
EC50 for HHA and UDA is not signiﬁcantly different from wild-type
virus, explaining its absence in CBA-escalating selection experiments.
We believe that sensitization to CBAs are not due to the loss of
replication ﬁtness because the data in Tables 1 and 3 do not reveal a
correlation between both phenomena.
Sensitization to HHA was also very recently observed for a mutant
virus strain containing the N295 glycan deletion selected under
pressure of the neutralizing, carbohydrate-binding antibody 2G12
(Huskens et al., 2007). It is possible that the disappearance of a
particular glycan on gp120 may result in a better accessibility of the
other glycans located nearby the deleted glycan position by the
relatively large tetrameric HHA protein (4×12.5 kDa). Indeed, HHA has
speciﬁcity for α(1,3)/α(1,6)-mannose oligomers that are present in
those interior parts of the complex-type glycans that are adjacent to
(GlcNAc)2 which is linked to the amide function of the glycosylated
asparagines. Deletion of one or more N-glycans in the dense glycan
shield of the gp120 V1/V2 domain may allow better availability of the
α(1,3)/α(1,6)-mannoses for HHA interaction. This may also be the case
for the smaller monomeric GlcNAc-speciﬁc UDA (8.7 kDa). Our
observation that the α(1,2)-mannose-speciﬁc small non-peptidic
PRM-A does not show an increased antiviral activity against the
mutant virus strains is in agreement with this interpretation, since the
complex-type glycans on gp120 V1/V2 do not contain the α(1,2)-
mannose conﬁguration, and thus, could not be targeted by PRM-A.
Although it cannot be excluded that CBA binding to V1/V2 gp120
glycans does not lead to neutralization or that the CBAs do not bind at
all to the V1/V2 glycans, both the decreased ﬁtness of mutant (V1/V2
glycan-deleted) HIV and the increased sensitivity to CBAs against
these virus strains argue for the V1/V2 gp120 domain as a target for
speciﬁc drug development that forces the virus to delete its glycans in
V1/V2 gp120. Thus, the maintenance of the V1/V2 glycans under CBA
pressure may indicate an important functional role of the glycans in
the V1/V2 domain and suggest that they may represent novel targets
for speciﬁc therapeutic intervention. This premise is additionally
supported by the observation that the glycans at positions 156, 160,
186 and 195 of the V1/V2 loops are highly conserved among a wide
Fig. 4. Allocation of putative N-glycosylation sites in group M viruses. Alignment of envelope glycoprotein sequences was obtained from the HIV Sequence Database (http://hiv-web.
lanl.gov) and subjected to analysis with the program N-glycosite (Zhang et al., 2004) for the allocation of putative N-glycosylation sites. The protein alignments contain all complete
gene sequences that were available within the database (September 2007), with the important exception that very similar sequences (e.g. multiple clones from one isolate, multiple
sequences from one person) have been deleted. Based on these results the fraction that represents a N-linked glycosylation site at each sequence position in the alignment was
calculated and visualized. The numbers at the top of each of the vertical lines represent the asparagine positions in gp120 according to Kwong et al. (1998). Underlined numbers
represent high-mannose type glycosylation sites. The other positions are complex-mannose type. The exact positions of 136 and 141 are difﬁcult to assign and therefore, they are
displayed in italic. Numbers between parentheses represent glycosylation sites that were not present in the HIV-1(IIIB) strain that was used in our experiments. Vertical lines are red-
colored when mutated in at least one of the isolates that were obtained after resistance selection experiments with CBAs.
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and 141 are difﬁcult to assign due to considerable amino acid
variability in this area of V1/V2, but it is clear that a glycan must be
present on, or in the vicinity of, amino acid positions 136 and 141. This
points to the importance of the presence of a glycan at, or near to,
positions 136 and 141 of V1/V2. Besides searching for novel CBAs that
speciﬁcally interact with the glycan conﬁguration on gp120 V1/V2,
attempts should also be made to produce monoclonal antibodies
(mAb) that selectively recognize the glycans on the gp120 V1/V2
domain. This must be a feasible and achievable goal as examples of
speciﬁc glycan-recognizing antibodies exist (Pinter et al., 2005;
Warrier et al., 1994). Also, the 2G12 mAb is one of the very few
known broadly neutralizing anti-HIV antibodies directed against an
epitope on gp120 located around the C4–V4 region containing a
speciﬁc glycan conﬁguration (Calarese et al., 2003, 2005; Scanlan
et al., 2002; Trkola et al., 1996).
In conclusion, we believe that both sensitization to CBAs and
compromised infectivity upon glycan deletions in the gp120 V1/V2
envelope domain of HIV may explain why glycan deletions in V1/V2
rarely occur in the presence of escalating CBA pressure. This area of
HIV-1 gp120 may represent a novel hot spot for rational and speciﬁc
drug targeting of the HIV entry process due to its highly conserved
glycans and a lack of ﬂexibility in response to, and in the presence of,
CBA drug pressure.
Material and methods
Test compounds
The mannose-speciﬁc plant lectin from Hippeastrum hybrid (HHA)
and the N-acetylglucosamine-speciﬁc plant lectin from Urtica dioica
(UDA) were derived and puriﬁed from these plants as describedpreviously (Van Damme et al., 1988a; 1988b) and kindly provided by E.
J.M. Van Damme and W. Peumans (Ghent, Belgium). Pradimicin A
(PRM-A) was obtained from Prof. T. Oki and Prof. Y. Igarashi (Toyama,
Japan). The CXCR4 antagonist AMD3100 was obtained from AnorMed
(Langley, BC, Canada) and human soluble CD4 (sCD4) was purchased
from Prospec (Rehovot, Israel).
Cells
Human T lymphocytic C8166 cells were obtained from the
American Type Culture Collection (ATCC) (Manassas, VA, USA) and
were cultivated in RPMI-1640 medium (Invitrogen, Merelbeke,
Belgium) supplemented with 10% fetal calf serum (FCS) (Cambrex
Bio Science, Verviers, Belgium), 1% streptomycin, 2 mM L-glutamine
and 75 mM NaHCO3. Human embryo kidney cells (293T) were
purchased from the ATCC and cultivated in Dulbecco's Modiﬁed
Essential Medium (DMEM) supplemented with 10% FCS, 1% strepto-
mycin and 75 mM NaHCO3. U87/CD4+/CXCR4+, U87/CD4+/CCR5+ and
U87/CD4+/CXCR4+/CCR5+ cells (Princen et al., 2004) were obtained
from Prof. D. Schols (Leuven, Belgium) and cultivated in DMEM
containing 10% FCS supplemented with 0.4% geneticin (Invitrogen)
and 1% puromycin (Invitrogen) for selection of CD4, CCR5 and CXCR4,
respectively.
Viruses
The pNL4.3-Δenv-EGFP construct is used for production of wild-
type NL4.3 virus after recombination with env and expresses an
enhanced version of green ﬂuorescent protein (EGFP) located between
env and nef without affecting the expression of any HIV-1 gene. For
this molecular clone, the expression of EGFP in infected cells is a
measurement of virus production as described previously (Weber et
17J. Auwerx et al. / Virology 382 (2008) 10–19al., 2006). The construct pNL4.3-Δenv-EGFPwas a kind gift fromDr. M.
E. Quiñones-Mateu (Lerner Research Institute, Cleveland, OH, USA).
Construction of mutant molecular virus
The plasmid pBlue-env which encodes the env gene (Fikkert
et al., 2002; Weber et al., 2006) was used to generate a variety of
gp120 mutant viral strains with disrupted glycosylation sites at
positions N136, N141, N156, N160, N186 and N195, where Asn was
replaced by the closely related Gln. To generate the various
multiple glycosylation site-mutant viruses, random combinations
of these six glycosylation sites were introduced into pBlue-env
using the QuikChange Multi Site-Directed Mutagenesis Kit (Strata-
gene, Westburg, Leusden, The Netherlands). Brieﬂy, supercoiled
double stranded pBlue-env and a combination of six synthetic
primers containing the desired mutation were used (Table 4). These
primer sets were extended during temperature cycling using Pfu
Turbo DNA polymerase mixture. Subsequently, the product was
digested with DpnI, which selects for the synthesized DNA
containing the mutations and transformed in XL-10 Gold ultra-
competent bacteria (Stratagene). Plasmid DNA was puriﬁed by the
QIAgen miniprep kit (Qiagen, Venlo, The Netherlands). The
presence of combinations of glycosylation site mutations was
conﬁrmed by sequencing the gp120 gene.
Generation of mutant viruses by env chimeric virus technology
Various mutant PCR fragments were ampliﬁed from mutated
pBlue-env by means of a hot start PCR using Expand High Fidelity
Enzyme blend (Roche, Brussels, Belgium). The cycling conditions
were as follows: a ﬁrst denaturation step of 2 min at 95 °C,
followed by 35 cycles consisting of 15 s at 95 °C, 45 s at 55 °C and
3 min at 68 °C. A ﬁnal extension step was performed at 68 °C for
7 min. The various PCR products were puriﬁed and concentrated
using the QIAgen PCR Puriﬁcation Kit (Qiagen). Subsequently, 2 μg
of the puriﬁed and concentrated PCR product was co-precipitated
with 10 μg of pNL4.3-Δenv-EGFP, linearized by XbaI digestion and
co-transfected into 293T cells using the calcium phosphate method
like that described previously by Fikkert et al. (2002) and Weber et
al. (2006). Brieﬂy, 700,000 293T cells were seeded in a 6 cm-dish
and 2 M CaCl2 was carefully mixed with the DNA solution and
added to an equal amount of HEPES buffered saline (HBS). After
incubating 20 min at room temperature the mixture was added
directly to the 293T cells. One day after incubation at 37 °C the
supernatant was replaced by 2 ml of fresh medium. Positive
transfection was detected by ﬂuorescence microscopy. Recombinant
replication-competent viruses were harvested and further grown
on U87/CD4+/CXCR4+/CCR5+ cells to produce more infectious
viruses. After 3 to 5 days post-infection of the U87 cells, aliquots
of 1 ml were stored at −80 °C for subsequent infectivity (CCID50)
and drug susceptibility (EC50) determinations.
After the production of replication-competent viruses a genotyp-
ing of the HIV-1 env region of interest was performed. Proviral DNATable 4
Oligonucleotides used for the multi site-directed mutagenesis of the env gene
Mutation Sense primer sequence
N136Q 5′-GTGCACTGATTTGAAGCAGGATACTAATACCAATAGTAG-3′
N141Q 5′-GAATGATACTAATACCCAGAGTAGTAGCGGGAGAATG-3′
N156Q 5′-GGAGAAAGGAGAGATAAAACAGTGCTCTTTCAATATCAGC-3′
N160Q 5′-GATAAAAAACTGCTCTTTCCAGATCAGCACAAGCATAAG-3′
N160D 5′-GATAAAAAACTGCTCTTTCGACATCAGCACAAGCATAAG-3′
N186Q 5′-CTTGATATAGTACCAATAGATCAGACCAGCTATAGGTTG-3′
N195Q 5′-GGTTGATAAGTTGTCAGACCTCAGTCATTACACAGG-3′
The mutated codon is marked in bold.was extracted from cell pellets using the DNeasy Tissue Kit (Qiagen)
and sequenced as described previously (Van Laethem et al., 2005).
Determination of the replication ﬁtness of the deglycosylated HIV-1
strains using similar p24 levels for infection
Various deglycosylated HIV-1 strains containing equal amounts of
HIV-1 p24 antigen (40,000 pg p24/ml) were exposed to C8166 cells.
Starting at 1-day post-infection, cells were microscopically examined
during 8 consecutive days for the appearance of HIV-1-induced
cytopathogenicity. In addition, cells were ﬁxed in phosphate buffered
saline (PBS) containing 2% paraformaldehyde (PFA) and analyzed on a
FACS CantoII ﬂow cytometer (Becton Dickinson, San Jose, CA). Data
were analyzed with FACS Diva Software (Becton Dickinson) for EGFP
expression.
Determination of the replication ﬁtness of the deglycosylated HIV-1
strains using a similar number of infectious viral particles for infection
Because the use of p24 levels only provides a quantitative
determination of the HIV-1 particles, we also performed assays that
take the virus infectivity into account. Therefore, we examined the
replication capacity of the different mutant virus strains using a
similar amount of infectious viral particles as recently described by
Brockman et al. (2006). Prior to the assay, the amount of infectious
viral particles that were able to infect 0.1% of the C8166 cell culture at
3 days post-infection was determined for wild-type and mutant
(deglycosylated) virus strains. This amount of infectious viral particles
was used to infect 500,000 C8166 lymphocytes in a 24-well plate.
After 3 days of incubation at 37 °C, aliquots of cell suspensions that
contain at least 200,000 cells were collected and ﬁxed in 2% PFA. Fresh
medium was added to the remaining cell cultures. The ﬁxed cell
suspensions were analyzed for EGFP expression on a FACS CantoII and
normalized to the infection rate value on day 3 which was determined
to be approximately 0.1%. The collection of cell suspensions and
determination of EGFP expression was repeated for 2 more days.
Co-receptor usage of the deglycosylated HIV-1 strain
Inoculants of various deglycosylated HIV-1 strains were added to
104 U87/CD4+/CCR5+, U87/CD4+/CXCR4+ or U87/CD4+/CXCR4+/CCR5+
cells in a 96-well microtiter plate. Medium was replaced 2 h after
infection. The cell cultures were scored 3 days post-virus exposure for
viral replication by ﬂuorescence microscopy to detect EGFP
expression.
Susceptibility of mutant deglycosylated HIV-1 strains to carbohydrate-
binding agents (CBAs), AMD3100 and sCD4
The inhibitory effects of the antiviral compounds on HIV-1
replication in C8166 cell cultures were determined upon measure-
ment of the EGFP expression in a FACS CantoII ﬂow cytometer. The 50%
cell culture infective doses (CCID50) of the different HIV-1 strains were
determined by titration of the virus stocks in C8166 cells. For drug
susceptibility assays, C8166 cells were infected with 10 CCID50 of the
HIV-1 strains in the presence of ﬁve-fold serial dilutions of the
antiviral drugs. After 3 days post-infection, the concentration of each
compound achieving 50% reduction of EGFP expression, deﬁned as
EC50, was determined.
Binding of mutant deglycosylated HIV-1 gp120 to human sCD4
96-well Maxi-Sorp plates (Nunc Inc) were coated with 25 ng
human soluble CD4 in 50 mM carbonate buffer pH 9.6 for 60 min at
37 °C. Subsequently, the wells were blocked with phosphate buffered
saline, pH 7.4 with 0.05% Tween-20 (PBST) containing 5% BSA for
18 J. Auwerx et al. / Virology 382 (2008) 10–1960 min at 37 °C. After four washes with PBST, different mutant
deglycosylated virus strains containing a normalized amount of
150,000 pg p24 Ag pre-treated with 10% TritonX-100, were added
for 60 min at 37 °C. Subsequently, the wells were washed four times
with PBST and incubated with 0.2 μg primary sheep anti-gp120
antibody (Aalto, Dublin, Ireland) for 60 min at room temperature (R.
T.). After incubation, the wells were again washed four times with
PBST and incubated with a 1/1000 dilution of peroxidase conjugated
donkey anti-sheep IgG (Sigma, St.-Louis, MO) for 60 min at R.T. The
wells were washed four times with PBST and 0.4 mg/ml o-
phenylenediamine dihydrochloride (OPD) substrate (Sigma) diluted
in 0.05 M phosphate–citrate buffer, pH 5.0 containing 0.03% sodium
perborate was added for 5 min and the reactionwas stopped with 2 M
H2SO4. The absorbance at 492 nm was determined using a Saﬁre2
microtiter plate reader (Tecan). Speciﬁc absorbance was calculated
subtracting the value for substrate and buffer from the measured
value.
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